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Abstract
Background: Aberrant epigenetic patterns are central in the pathogenesis of haematopoietic diseases such as
myelodysplastic syndromes (MDS) and acute myeloid leukaemia (AML). Vorinostat is a HDACi which has produced
responses in these disorders. The purpose of this study was to address the functional effects of vorinostat in leukemic cell
lines and primary AML and MDS myeloid cells and to dissect the genetic and molecular mechanisms by which it exerts its
action.
Methodology/Principal Findings: Functional assays showed vorinostat promoted cell cycle arrest, inhibited growth, and
induced apoptosis and differentiation of K562, HL60 and THP-1 and of CD33+ cells from AML and MDS patients. To explore
the genetic mechanism for these effects, we quantified gene expression modulation by vorinostat in these cells. Vorinostat
increased expression of genes down-regulated in MDS and/or AML (cFOS, COX2, IER3, p15, RAI3) and suppressed expression
of genes over-expressed in these malignancies (AXL, c-MYC, Cyclin D1) and modulated cell cycle and apoptosis genes in a
manner which would favor cell cycle arrest, differentiation, and apoptosis of neoplastic cells, consistent with the functional
assays. Reporter assays showed transcriptional effect of vorinostat on some of these genes was mediated by proximal
promoter elements in GC-rich regions. Vorinostat-modulated expression of some genes was potentiated by mithramycin A,
a compound that interferes with SP1 binding to GC-rich DNA sequences, and siRNA-mediated SP1 reduction. ChIP assays
revealed vorinostat inhibited DNA binding of SP1 to the proximal promoter regions of these genes. These results suggest
vorinostat transcriptional action in some genes is regulated by proximal promoter GC-rich DNA sequences and by SP1.
Conclusion: This study sheds light on the effects of vorinostat in AML and MDS and supports the implementation of clinical
trials to explore the use of vorinostat in the treatment of these diseases.
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Introduction
Haematopoiesis is a complex, dynamic and controlled process
where a pluripotent stem cell differentiates into different cell
lineages. Growth factors, signaling transduction pathways and
transcription factors regulate differentiation, cell cycle and
apoptosis in these cells by modulating gene expression [1]. These
processes are deregulated in haematopoietic diseases such as
myelodysplastic syndromes (MDS) and acute myeloid leukemia
(AML) [2,3,4].
MDS is characterized chiefly by increased apoptosis and
progression to AML [2], whereas in AML there is a block in
differentiation and increased cellular proliferation of neoplastic
haematopoietic precursor cells [3,4]. Knowledge of their patho-
physiology has led to the development of novel treatment strategies
which, unlike traditional cytotoxic therapies, use epigenetic agents
to modulate gene expression.
Epigenetic modifications are important mechanisms by which
cells regulate the expression of genes. Emerging data in the last
decades revealed epigenetic changes play an important role in the
pathogenesis of haematopoietic malignancies by silencing tumour
suppressor genes and altering the expression of genes involved in a
multitude of cellular functions [2,3,4,5,6,7,8]. Some of these
epigenetic changes may be pharmacologically manipulated, such
as with histone deacetylase inhibitors (HDACi), which are
emerging as promising anti-cancer agents for the treatment of
patients with MDS and AML [2,3,9,10].
Vorinostat is a hydroxamic acid HDACi which promotes
protein acetylation, modulates gene expression, and induces
differentiation, growth arrest, and apoptosis of tumour cells
[11,12], and has shown promising clinical activity against
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haematological and solid tumours [10,13,14]. Clinical trials
revealed vorinostat has only moderate haematologic toxicity and
in vitro studies showed vorinostat exhibits low toxicity against
normal cells [11,12,15]. Vorinostat anti-tumoural activity is
believed to result from its ability to modulate gene expression,
generate oxidative stress, and induce DNA damage and genomic
instability [10,16,17].
The transcriptional effect of several HDACi on some genes is
SP1 dependent [18,19,20,21,22,23,24,25]. SP1 is a zinc finger
transcription factor (TF) that regulates transcription of genes
containing GC-rich DNA sequences in their promoters by
modulating histone acetylation. SP1 regulates a variety of
biological functions, including cell survival, growth, differentiation,
and tumour development and progression [26].
Although the use of vorinostat for the treatment of haemato-
logical malignancies has increased substantially over the last years
[10], the characterization of its effects on leukemic and MDS cells
remains incomplete. The knowledge of the effects of vorinostat in
these cells might contribute to a better understanding of its
mechanisms of action, which may ultimately assist in its clinical
application.
Our aim in this study was to document the functional effects of
vorinostat in cell lines derived from patients with AML and
primary AML and MDS myeloid cells and to contribute to the
knowledge of the genetic and molecular mechanisms by which it
exerts its action. Its functional effect was studied through cell cycle
progression, apoptosis and differentiation assays. In an effort to
explain the genetic mechanism by which these effects were
obtained, we measured the modulation of expression of genes
known to be involved in cell cycle regulation, apoptosis and
oncogenesis, some of them known to be altered in MDS and/or
AML [7,8,27,28,29,30]. In an attempt to dissect the molecular
mechanism of its action we analyzed the DNA sequence elements
involved in vorinostat-mediated gene expression. In addition we
analyzed vorinostat interaction with SP1.
Materials and Methods
Cell Lines, Patient Cells and Reagents
The human HL60 promyelocytic (AML M2/3, FAB classifica-
tion), THP1 monocytic (AML M5) and erythroleukaemic K562
(myeloid blast crisis chronic myelogenous leukaemic cells with
properties of AML M6) cells were cultured at 37uC and 5% CO2
in RPMI-1640 medium with 10% fetal calf serum, 2 mM L-
glutamine, 100 mg/ml penicillin and 100 U/ml streptomycin (Life
Technologies) in the presence of vorinostat (0.5–5 mM) or vehicle.
Cells in logarithmic growth phase between passages 7 and 25 were
used for these assays.
Peripheral blood (PB) samples from 8 patients with AML (3
monocytic (AML M5), 3 myelomonocytic (AML M4) , and 2
myeloblastic (AML M2)) and bone marrow (BM) aspirates from 9
patients with high risk MDS were obtained following informed
consent and in the course of routine clinical workup. This project
was approved by the local ethics committee and all samples were
treated in accordance with institutional ethical regulations.
Mononuclear cells (MNC) from PB and BM samples were
separated by density gradient centrifugation through Ficcoll-
Hypaque (Sigma) and CD33+ MNC isolated with human anti-
CD33 microbeads (Miltenyi Biotec) as per manufacturers instruc-
tions. CD33+ cells (0.4–16106/ml) were cultured in RPMI-1640
or in Iscove’s Modified Dulbecco’s Medium (IMDM; Sigma) with
10% FCS, 2 mM L-glutamine and 100 mg/ml each penicillin and
streptomycin (Life Technologies), 2 ng/ml SCF, 0.025 ng/ml
GM-CSF, 0.025 ng/ml G-CSF, 0.1 ng/ml IL-3, 0.008 ng/ml IL-
6 (Life Technologies) and 0.5 ng/ml EPO (Sigma) in the presence
of vorinostat (0.5–5 mM) or vehicle.
Vorinostat (Selleck Chemicals), phorbol-12-myristate-13-acetate
(PMA), and mithramycin A (Mith.A) (both from Sigma) were
diluted in DMSO. Working solutions were prepared in PBS.
Gene Expression Analysis (qPCR)
Total RNA was isolated from cells (0.7–16106/ml) cultured in
complete RPMI plus vorinostat or vehicle (control) using the
RNeasy Midi kit (Qiagen) according to the manufacturers
instructions. cDNA was obtained from equal amount of purified
RNA as described in [31]. Gene expression was quantified on
Roche LightCycler 480 with gene specific primers for human
Apoptosis and Cell cycle PCR Arrays (PAHS-3012G and PAHS-
020F, SABiosciences). Results were normalized to HPRT1 mRNA
in the same sample (or to B2M, HPRT1, RPL13A, and GAPDH
mRNAs in the case of PCR Arrays) and calculated as fold change
relative to control cells treated with vehicle. All experiments and
analysis were carried out according to manufacturer’s instructions.
Cell Cycle Analysis
Cell cycle progression was determined by flow cytometry using
propidium iodide (PI). Cells (105/ml) were cultured with
increasing concentrations of vorinostat (1–5 mM) or vehicle
(control) for 15, 24, 36 (all three cell lines) and 48 h (K562 and
HL60), washed with PBS and fixed with ice-cold 70% ethanol.
After 2 h, cells were washed twice in PBS and resuspended in PBS
containing 50 mg/ml PI (Sigma), 200 mg/ml DNase free RNase A
(Citomed), and 0,1% Triton X-100 for 1 h at room temperature.
Acquisition was performed on a FACSCalibur flow cytometer
(Becton Dickinson). Data were analyzed with the cell cycle
program from FlowJo software (Tree Star, Inc. Ashland, OR).
Cell Viability, Growth and Apoptosis
Cell viability was measured using the MTT (Sigma) colorimetric
method. In short CD33+ cells were seeded in 96-well plates
(100 ml/well) and exposed to varying concentrations of vorinostat.
After 24–72 h treatment, 20 ml of MTT solution (20 mg/ml) was
added to each well and cells incubated for 16 h. Thereafter, the
resulting MTT crystals were dissolved in DMSO (120 ml/well) and
absorbance measured at 490 nm using an ELISA microplate
reader. Each concentration of the drugs was tested in triplicates.
Cell growth was determined by microscopy using the trypan blue
exclusion method. Apoptosis of cells co-stained with FITC-
conjugated annexin-V (BD Biosciences) and PI or 7-AAD (BD
Biosciences) was measured by flow cytometry as in [32].
Flow Cytometry
Immunoflorescent staining was performed according to stan-
dard protocols. PE-CD33 antibody (BD biosciences) was used to
assess CD33+ purity after positive selection. To assess vorinostat
effect on differentiation of K562, HL60, cells (0.4–0.66104/ml)
were cultured for 3 to 5 days in the presence of vorinostat (0.5–
5 mM) or vehicle (control) in complete RPMI-medium in the
presence or absence of GM/G-CSF or EPO as described
elsewhere. To study differentiation of THP1 by vorinostat, cells
(56105/ml) were cultured for 3 to 4 days in the presence of
vorinostat (0.5–2 mM) or vehicle in complete RPMI-medium.
Every 2 day half of the medium was replaced by fresh medium as
above. PB-CD33 cells from AML patients and BM-CD33 cells
from high risk MDS patients (0.4–0.66104/ml) were cultured in
complete IMDM medium with SCF, IL-3, IL-6, GM-CSF, G-
CSF, and EPO in the presence of 0.5–2 mM vorinostat or vehicle
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for 3 day. At day 3, 4 and 5 cells were harvested, stained and
analyzed by flow cytometry.
Erythroid differentiation of K562 was assessed by co-staining
cells with CD235A-PE (Beckman Coulter) and CD71-FITC (BD
Biosciences) antibodies as in [33]. Myeloid differentiation of HL60
and CD33+ was evaluated with CD11b-PE plus CD13-APC, and
CD11b-PE plus CD13-APC and CD14-FITC antibodies (Biole-
gend), respectively [34]. During neutrophil maturation four
different stages of increasing maturation are defined based on
the expression of CD13 and CD11b antigens. Stage I, CD13hi/
CD11b2 myeloblasts; stage II, CD13lo/int/CD11b2 promyelo-
cytes; stage III, CD13lo/int/CD11b+ myelocytes and metamyelo-
cytes, and stage IV, CD13hi/CD1b+ bands/mature neutrophils.
Monocytic maturation from monoblasts through promonocytes
and monocytes is characterized by acquisition of CD11b and
CD14. Most mature monocytic cells display bright CD14, CD11b
and CD13 expression. Monocytic differentiation of THP1 cells
was assessed by co-staining cells with CD11b-PE plus CD14-FITC
antibodies. Acquisition was performed on a FACSCalibur and
analysis with the FlowJo software. Specific labeling was compared
with nonspecific staining using fluorescent-labeled isotype-
matched control antibodies.
K562 Cytological Staining and Hemoglobin (Hb)
Determination
K562 cells (0.4–0.66104/ml) were cultured for 4 days at 37uC
with 5% CO2 in RPMI-1640 medium with 10% fetal calf serum,
2 mM L-glutamine, 100 mg/ml penicillin and 100 U/ml strepto-
mycin (Life Technologies) supplemented with 0.5 ng/ml EPO
(Sigma) in the presence of vorinostat (1–5 mM) or vehicle. Every 2
day half of the medium was replaced by fresh medium as above.
At day 4 after treatment, cells were harvested, washed with PBS,
and vorinostat effect in terminal erythroid differentiation of K562
was assessed by measuring Hb content by ELISA and by
microscopy of benzidine (to detect Hb) plus Giemsa stained cells.
For benzidine–Giemsa staining, cells (26103 per culture) were
centrifuged onto glass slides (2 min at 400 rpm), air dried, fixed
(220uC methanol) and stained with 3,39-diaminobenzidine (TMB)
and Giemsa stains according to the manufacturer’s recommenda-
tions (Sigma). Images were acquired on a Zeiss Axioplan
microscope equipped with a Zeiss Axioxcam MRm (amplification:
x200). For hemoblogin quantification by ELISA, the cell pellet was
resuspended in lysis buffer (100 mM potassium phosphate pH 7.8,
0.2% Triton X-100) and incubated 10 min at room temperature.
After pelleting cellular debris, the supernatant was collected and
20 ml was incubated with 80 ml TMB solution (2 mg/ml in 0.03%
glacial acetic acid) containing H2O2 (0.03%). After 30 min
incubation at room temperature in the dark, the enzymatic
reaction was stopped by adding 50 ml of 1 N H2SO4 and
absorbance was measured at 490 nm. A standard curve was
generated by using known concentrations of human Hb (Sigma) as
an internal control in each experiment. The amount of Hb in the
cellular lysates was determined from the standard curve. After
measurement of protein concentration of the lysate by the
Bradford method, nanograms of Hb per micrograms of total
cellular protein was calculated.
Plasmids
DNA fragments containing the 2-1.5-kb proximal promoter and
the 59-UTR sequences of IER3, COX2 and cFOs genes were
amplified from normal PB-MNC genomic DNA by PCR with
promoter specific primers using the Expand Long Template PCR
system (Roche) and cloned into the pGL3-basic plasmid (Promega)
according to standard protocols. Progressive deletion reporter
plasmids were generated by PCR using specific primers and the 2-
1.5-kb reporter constructs. IER3 261/+32 and 231/+32 reporter
plasmids were generated by inserting oligonucleotides containing
these promoter sequences into pGL3-basic plasmid. Reporter
constructs with mutations in the putative TF binding sites of the
IER3 promoter were generated using the 2124/+32 IER3
reporter construct as template and mutagenic primers using the
QuikChange site-directed mutagenesis kit (Stratagene). Reporter
plasmids were amplified in Escherichia coli XL-2Blue (Promega)
and DNA purified using DNA isolation kit (Qiagen). All reporter
constructs were verified by sequencing.
Reporter Assays
K562 and HL60 cells (105 cells/ml well of 24-well plate) were
transiently co-transfected with 400 ng indicated wild-type and
mutated reporter constructs or with pGL3-basic control vector
(Promega) plus 25 ng b-galactosidase reporter control expression
vector (Promega) using 4 ml lipofectamine 2000 (Life Technolo-
gies) as per manufacturers protocol. 1 h after transfection cells
were treated with 2 mM vorinostat or vehicle (control). 24 h later,
cells were harvested, and luciferase and b-galactosidase activities of
cell lysates measured using the Single Luciferase Assay System
(Promega) and the Galacto-Light plus b-Galactosidase. Luciferase
activities were normalized to b-galactosidase units in the same
samples. Results are shown as average fold induction versus control
cells transfected with pGL3 6 S.D. from one representative of at
least three independent assays done in triplicate using each
reporter construct at least from two different clones.
Chromatin Immuneprecipitation (ChIP) Assays
K562 and HL60 cells (106/ml) were treated with 5 mM
vorinostat or vehicle for 7 h. Chromatin was cross-linked and
sheared to 200–700 bp size according to the Shearing Chip Kit
instructions (Diagenode) and immunoprecipitated with anti-SP1
polyclonal antibodies (Abcam ab13370 and Millipore 17–601) and
isotype control IgG at 4uC during 16 h as described in the
OneDay ChIP Kit protocol (Diagenode). After DNA recovery, the
precipitates were evaluated by real time PCR with primers specific
for the cFOS (2290/+8), COX2 (2356/233), Cyclin G2 (2288/
+15), IER3 (2100/+20), p21 (2174/+39), and CUL1 (231/+41)
promoter sequences. SP1 occupancy was calculated according to
the OneDay ChIP Kit protocol. Results are expressed as fold
change over control IgG and represent average values of at least
three independent experiments 6 SEM.
SP1 Silencing and Western Blotting
K562 were transfected by electroporation with 100 nM of
pooled SP1-specific or control siRNAs (L-026959-00-0005 and D-
001210-03-05, respectively, Dharmacon) per 106 cells as described
in [35]. 4 h after transfection cells were treated with 2 mM
vorinostat or vehicle (control). All assays were done in triplicate.
SP1 knockdown was monitored 24 h thereafter by qPCR, and 48
and 72 h after transfection by Western blotting as described in
[32]. SP1 protein was detected with mouse anti-human SP1
antibody (Santa Cruz Biotechnology sc-420X) and a-tubulin with
a mouse anti-human a-tubulin monoclonal antibody (Sigma
T9026). Primary antibodies were detected using horseradish
peroxidase-conjugated goat anti-mouse IgG secondary antibody
(Pierce). The experiments on SP1 knockdown effect on the
expression of genes modulated by vorinostat were performed at 48
and 72 h after siRNA transfections by qPCR. Results were
normalized to HPRT1 mRNA in the same sample and calculated
as fold change over control cells treated with vehicle and
transfected with the same siRNA.
Vorinostat in AML and MDS: Effects and Mechanisms
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Bioinformatics
Gene sequences were obtained from GenBank and Ensembl
databases. Analysis of promoter regions was performed with the
Transcription Element Search System (TESS). Primers were
designed with the Primer Express 3.0 software (ABI, Life
Technologies), and NCBI primer express tool (http://www.ncbi.
nlm.nih.gov/tools/primer-blast/). The sequences of all primers
are available on request.
Statistics
Statistical significance was determined using two-tailed Students
t-test and the ANOVA and the Tukey-Kramer multiple compar-
ison test. A value of p,0.05 was considered significant.
Results
Vorinostat Promotes Cell Cycle Arrest and Subsequent
Apoptosis of K562, HL60, and THP1
In order to be effective in MDS and AML, vorinostat would
have to induce cell cycle arrest and commit neoplastic cells to
apoptosis. This hypothesis was tested by flow cytometric analysis of
cell cycle and apoptosis of leukemic K562, HL60, and THP1 cells
treated with vorinostat. Our results revealed that vorinostat
induced cell cycle arrest of K562, HL60 and THP1 cell lines. In
K562 incubation with 3–5 mM vorinostat for 15–24 h caused G1
and G2/M arrest accompanied by a significant reduction of cells
in the S phase and a subsequent accumulation of cells in the sub-
G1 population (Figure 1A and B and Figure S1A and S1B). In
HL60 15 h exposure to vorinostat caused significant G2/M arrest
and reduction of cells in the G1 and S phases in a dose dependent
manner (Figure 1A and B) with later accumulation in the sub-G1
population (data not shown). Treatment of THP1 cells with 1 mM
vorinostat for at least 24 h caused substantial G1 arrest with
significant reduction of cells in the S and G2/M phases of the cell
cycle (Figure 1A and B).
The significant accumulation of cells in the sub-G1 population
suggests these were undergoing apoptosis. This was verified by
flow cytometry by staining treated cells with annexin-V and PI/7-
AAD. No significant apoptosis was observed until at least 24 h
post-treatment. At 48 h, 2.5 mM vorinostat induced significant
apoptosis in K562 (P = 0.03) and HL60 (P,0.001) (Figure 1C and
D), consistent with the accumulation of cells in sub-G1 at this time
point. After 72 h treatment, lower (1.5–2 mM) vorinostat concen-
trations induced significant apoptosis of K562 and HL60 cells
(Figure 2C and G, and Figure S1C and S1D). In both cases,
vorinostat induced considerably more apoptosis in HL60 than in
K562. In THP1 48 h treatment with 1 mM vorinostat induced
substantial apoptosis (P = 0.0001) (Figure 1C and D). THP1 cells
were those most sensitive to the apoptotic effects of vorinostat.
Overall these results show that vorinostat induces cell cycle
arrest and apoptosis of K562, HL60 and THP1. The three cell
lines have different sensitivities to vorinostat, HL60 and THP1
being substantially more sensitive to vorinostat-mediated cell cycle
arrest and apoptosis than K562.
Vorinostat Inhibits Growth and Promotes Differentiation
of K562, HL60, and THP1
Given that increased proliferation and differentiation block are
hallmark features of MDS and AML [2,3], we analysed the effect
of vorinostat on these cell lines’ growth and differentiation, as
determined by trypan blue exclusion by microscopy and flow
cytometry. As shown in Figure 2, after 3 days of treatment,
vorinostat inhibited growth (Figure 2A) and promoted erythroid
differentiation of K562, as reflected by the increase of more
mature CD235A+/CD712 cells from 3% to 50% (Figure 2B and
D), and induced apoptosis (Figure 2C and D). However, vorinostat
did not increase hemoglobin content as detected by both
benzidine–Giemsa stain and ELISA in K562 cells at the end of
3 to 5 days treatment (Figure S2). Significantly, this effect was
identical to that obtained with EPO (data not shown).
Myeloid maturation in HL60 was based on the identification of
four different stages of increasing maturation, defined according to
the expression profile of CD13 and CD11b [34], as determined by
flow cytometry. As shown in Figure 2E–H, vorinostat inhibited
growth (Figure 2E) and promoted HL60 terminal differentiation in
a dose dependent manner (P,0.05) (Figure 2F and H). Maximal
HL60 terminal myeloid maturation is observed at vorinostat
concentrations that substantially inhibit growth and induce
apoptosis. When treated with 1–1.5 mM vorinostat, HL60 cells
that are composed by myeloblasts (stage I cells) and promyelocytes
(stage II cells), are composed by myelocytes/metamyelocytes (stage
III cells) and mostly by bands/mature neutrophils (stage IV cells).
DMSO was used as a positive control [36] and GM-CSF plus M-
CSF produced identical results (data not shown).
THP-1 cell line is composed by monoblasts and promonocytes
committed to the monocytic cell lineage [37]. Monocytic
differentiation of THP1 cells was determined according to the
expression of CD11b and CD14 by flow cytometry. PMA was
used as positive control. As shown in Figure 2I–N, following 3
days’ incubation, vorinostat (0.5–1.5 mM) inhibited growth and
induced apoptosis of THP1 in a dose dependent manner and
promoted their differentiation as reflected by increased expression
of the monocytic differentiation marker CD11b and increased
percentage of CD11b+ cells. THP1 cells treated with 0.5 mM
vorinostat, a concentration that caused significant growth inhibi-
tion but not apoptosis, increased the expression of CD11b by 2.5
fold versus control cells and the percentage of CD11b+ cells from
75% to almost 100% (Figure 2J, K and N). At 1.5 mM, a
concentration that caused considerable growth arrest and apop-
tosis, vorinostat induced a greater degree of THP1 differentiation,
as reflected by the simultaneous expression of CD11b and CD14,
a marker of mature monocytes (Figure 2L–N).
Overall this series of results show vorinostat inhibits cell
proliferation and promotes differentiation of K562, HL60 and
THP1. The sensitivities of the different cell lines to vorinostat
varied, with a greater degree of differentiation but also more
apoptosis seen in HL60 and THP1.
Vorinostat Induces Apoptosis and Promotes
Differentiation of AML and MDS CD33+ Cells
The effects of vorinostat observed in HL60 and THP1 cells were
confirmed in CD33+ cells isolated from blood of patients with
AML (AML PB-CD33). Myeloid and monocytic differentiation
was determined according to the expression of CD13, CD11b and
CD14 by flow cytometry. Following 3 days’ incubation, vorinostat
(0.5–1 mM) induced differentiation of these cells as demonstrated
by increased proportions of more mature CD13/CD11b myeloid
populations (CD13lo/int/CD11b+, and mostly CD13hi/CD11b+)
and decreased proportions of the two more immature CD13/
CD11b populations (CD13hi/CD11b2 and CD13lo/int/CD11b2),
and also by increased percentage of mature monocytes, i.e.
CD14+/CD11b+ cells (Table 1 and Figure 3A). As in the case of
leukaemic cell lines, vorinostat also significantly increased apop-
tosis, suggesting these two events are correlated.
Since epigenetic changes are implicated in both AML and MDS
and a significant proportion of MDS patients transform to AML
[2,3,8], we evaluated whether vorinostat promoted differentiation
Vorinostat in AML and MDS: Effects and Mechanisms
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Figure 1. Functional impact of vorinostat in cell cycle progression and apoptosis of K562, HL60, and THP1 cells. A, K562, HL60 and
THP1 cells were cultured with vorinostat or vehicle (Control/Cont) as indicated and cells were analyzed by flow cytometry after 15 h (K562 and HL60)
and 36 h (THP1). Graphs show average percentage of cells in each phase of the cell cycle 6 SD of three independent assays for K562 and HL60 and
two different experiments for THP1, each in triplicate. B, Representative histograms showing the effect of vorinostat in K562, HL60 and THP1 cell cycle
progression. Cells arrested in the G1 phase, 2 N DNA content; cells arrested in S phase; and cells arrested in the G2/M phase (4 N DNA content). C,
K562, HL60 and THP1 cells were cultured in the presence of vorinostat or vehicle as indicated and apoptosis was analyzed 48 h thereafter by flow
Vorinostat in AML and MDS: Effects and Mechanisms
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of myeloid cells from MDS patients. As shown in Figure 3B,
vorinostat induced similar differentiation effects in CD33+ cells
isolated from bone marrows of patients with high risk MDS (MDS
BM-CD33). Vorinostat (1 mM) promoted a 3 fold increase of the
percentage of stage III cells in patient 1, and a 2 fold increase of
stage II cells in patient 2, and induced apoptosis.
Vorinostat Modulates the Expression of Genes Involved
in Cell Cycle Control, Proliferation, Apoptosis, and
Differentiation of Haematopoietic Cell Lines
In order to understand the mechanisms through which
vorinostat may exert its functional effects, we first assessed the
effect of vorinostat on the expression of the following groups of
genes:
1. cell cycle control, proliferation, apoptosis, differentiation
a. altered in MDS and/or AML [7,8,27,28,29,30] (Figure 4A,
1);
b. altered in MDS and/or AML and known to be modulated
by epigenetic agents [7,8,27,28,29] (Figure 4A, 2);
2. transcription factors involved in oncogenesis [26,38] (Figure 4A,
3).
In K562, HL60 and THP1 vorinostat (1–2 mM/8 h) signifi-
cantly modulated the expression of genes involved in cell cycle
control, proliferation, apoptosis, differentiation and oncogenesis.
Specifically, IER3, RAI3, cFOS, COX2, STAT2 and Gravin,
frequently suppressed in MDS patients [7,8], were significantly up-
regulated by vorinostat in both cell lines (Figure 4A, 1 and 2),
whereas c-MYC, a major player in haematopoiesis and often
deregulated in many haematological disorders [39], and MZF1,
involved in oncogenesis progression [38], were significantly down-
regulated (Figure 4A, 1 and 3). In THP1 the effect of vorinostat on
the expression of most of these genes was less pronounced than in
K562 and HL60. Interestingly, some genes, such as p15
(Figure 4A, 1), and Cyclin D1 (Figure 4A, 2), often deregulated
in MDS and AML and associated with worse prognosis
[7,40,41,42], were modulated to a greater extent in HL60,
whereas AXL (Figure 4A, 1), frequently up-regulated in AML and
associated with adverse prognosis [30], was more marked in K562.
Using cell cycle and apoptosis PCR arrays, we next assessed the
effect of vorinostat in other cell cycle and apoptosis genes, as these
genes are key players in haematological malignancies [43]. We
found that, in K562, vorinostat induced a 4 fold or greater change
in 9 cell cycle and 21 apoptosis genes. These findings were
confirmed in K562, HL60 and THP1 cells by qPCR (Figure 4B
and C). Vorinostat induced transcription of genes involved in cell
cycle arrest (p21 and Cyclin G2) [44] and DNA repair (RAD9A)
[45] and decreased the expression of NBN, a double strand break
repair gene in all cell lines (Figure 4B, 4). Up-regulation of cell
cycle arrest genes by vorinostat was more marked in HL60. Down-
regulation of cell cycle transition genes was more marked in K562
than in THP1 and HL60 (Figure 4B, 5).
The effect of vorinostat on the expression of apoptosis genes (all
genes in Figure 4C, p21 in Figure 4B, and IER3 in Figure 4A)
differed between the three cell lines: in K562 15 apoptosis genes
were up-regulated and 6 down-regulated whereas in HL60 cells 16
apoptosis genes were up-regulated and 2 down-regulated. In
THP1 13 apoptosis genes were up-regulated and 3 down-
regulated, showing that modulation of apoptosis genes by
vorinostat was relatively lower in THP1 cells when compared to
the other cell lines. In all cell lines vorinostat significantly increased
the transcription of the pro-apoptotic genes CD40, HIP1,
PPP1R13B, TP63 and NOTCH2 , did not affect expression of
IFT57 and LTBR in HL60 and LTBR, RUNX3 and TNFRSF9
in THP1 (Figure 4C, 6). Vorinostat suppressed the pro-apoptotic
genes CARD9 and TNFRSF8 in the three cell lines, FOXL2 in
K562 and THP1 cells, and LTBR only in K562 (Figure 4C, 6).
The anti-apoptotic genes up-regulated by vorinostat in the three
cell lines included genes coding for caspase inhibitors (i.e. IFI6 and
SERPINB9) and proteins involved in signal transduction pathways
with multifaceted functions (i.e. DDAH2, MAPK8IP2, SEMA4D)
[46,47] (Figure 4C, 7). Of note, NFkB1 was suppressed in K562
and THP1 cell lines and STAT5A only in K562.
Collectively, these data demonstrate that, at clinically relevant
concentrations (i.e. 1 and 2 mM) [14,48], vorinostat modulates
gene expression in K562, HL60, and THP1 cells in a manner
consistent with the promotion of cell cycle arrest, differentiation
and apoptosis. Of note, similar gene expression profiles were
obtained with 5 mM vorinostat in K562 and HL60 cells after 8 h
incubation (data not shown).
Vorinostat Modulates the Expression of Genes Involved
in Cell Cycle Control, Proliferation, Apoptosis, and
Differentiation in Primary Myeloid Cells from AML and
MDS Patients
These profiles of modulation of gene expression by vorinostat
were confirmed in PB-CD33 cells from AML patients with
circulating blasts. As shown in Figure 5A, the effect of vorinostat
(5 mM/8 h) on the expression pattern of genes altered in MDS
and/or AML, with the exceptions of STAT2, Gravin and Cyclin
D1, mirrored that observed in K562, HL60, and THP1 cell lines:
p15, RAI3 and COX2 were significantly up-regulated, IER3 and
cFOS moderately up-regulated, c-MYC, AXL and MZF1
suppressed. Interestingly, Cyclin D1, which is induced by
vorinostat in HL60, is significantly down-regulated by this agent
in primary AML cells. The modulation of expression of STAT2
and Gravin was not consistent between different patients
(Figure 5A, 2).
In AML PB-CD33 cells, the effect of vorinostat on the
expression of genes involved in cell cycle regulation also mirrored
that seen in cell lines, albeit to a lesser extent. p21, Cyclin G2,
RAD9A and ANAPC2 were induced whereas NBN and CUL1
were suppressed. Exception was CDK4 that was significantly up-
regulated in these cells (Figure 5B) contrary to the cell lines where
it was either suppressed (K562) or unaffected (THP1 and HL60).
In primary cells, vorinostat substantially increased transcription of
the pro-apoptotic caspase activating genes FOXL2, unlike that
seen in K562 and THP1 and induced considerable higher levels of
IFT57 as compared to the cell lines. In primary cells there was no
consistent effect on the expression of CD40, HIP1, LTBR,
RUNX3, TNFRSF9 and TP63 by vorinostat (Figure 5C, 6). As in
the case of K562, HL60 and THP1, CARD9 and TNFRSF8 were
suppressed.
cytometry. Graphs show average percentage of K562, HL60 and THP1 apoptosis 6 SD of three independent assays, done in triplicate. D,
Representative dot plots showing the percentage of apoptotic K562, HL60 and THP1 cells cultured for 48 h in the absence and in the presence of
vorinostat. Numbers are percentages of total cells in the respective gates from one of three independent experiments for each cell line. *p,0.05.
doi:10.1371/journal.pone.0053766.g001
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Figure 2. Effect of vorinostat on growth and differentiation of K562, HL60 and THP1 cells. K562 (A–D), HL60 (E–H) and THP1 (I–N) cells
were treated with vorinostat as indicated, vehicle (Control/C), DMSO (1.5%) or PMA (10 nM). After 3 days, K562, HL60 and THP1 cellular growth was
determined by trypan blue exclusion method, and surface markers and apoptosis by flow cytometry. A, Average percentage of K562 cells 6 SD of
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Vorinostat significantly up-regulated NOTCH2 and anti-
apoptotic genes DDAH2, IFI6, MAPK8IP2, SEMA4D, SER-
PINB9 and down-regulated NFkB1 in primary cells similarly to
that seen with the K562 and THP1 cell lines. No consistent effect
was seen on the expression levels of STAT5A (Figure 5C, 7).
The same experiments were performed on CD33+ cells isolated
from the bone marrows of patients with MDS (MDS BM-CD33).
Figure 6 shows that the effects vorinostat (5 mM/8 h) on the
expression of the same panels of genes described above in MDS
BM-CD33 cells was comparable to that observed in PB-CD33
cells from AML patients (Figure 5). Exceptions were p15 and
RAI3 that were not up-regulated in cells from all MDS patients;
Gravin and STAT5A that were down-regulated in cells from all
MDS patients; and Cyclin D2, CDK4, and CDK6 which were
down-regulated in most MDS patients cells as compared to AML
PB-CD33 cells.
Therefore, the overall effect of vorinostat on the expression of
apoptosis genes in primary PB and BM CD33+ cells is pro-
apoptotic and similar to that seen in THP1 but less marked than
that observed in K562 and HL60 despite different profiles of gene
expression.
In summary, vorinostat alters the profile of expression of genes
involved in proliferation, apoptosis and differentiation leading to a
pattern that would predict inhibition of cell proliferation and
increase in differentiation. This is consistent with its functional
effect on haematopoietic cell lines and primary cells.
Vorinostat Responsive Promoter Elements of IER3, cFOS
and COX2 Genes are Located within their Proximal
Promoter Regions
To explore the molecular mechanism by which vorinostat
modulates gene expression, reporter plasmids containing different
portions of the promoter regions of IER3, cFOS and COX2, some
of those genes which we found to be most responsive to vorinostat,
were generated and used in reporter assays in K562 and HL60.
The luciferase activity of the full length IER3, cFOS and COX2
reporter plasmids was significantly enhanced by treatment with
vorinostat (Figure 7A and Figure S3). Deletions of the IER3
promoter sequence between 22000 and 2163 slightly reduced the
promoter activity in K562 (Figure 7A) and HL60 (data not shown)
but had no significant effect on the vorinostat-mediated enhance-
ment. However, deletion of the sequence 291 to 261 abolished
both vorinostat-mediated and basal promoter activities. Results
obtained with cFOS and COX2 reporter plasmids indicate their
vorinostat-responsive elements are located in the 2449/+155
region of cFOS and downstream of 2246 of COX2 (Figure S3).
The 291/261 region of IER3 contains binding sites for the
transcription factors CP2, AP2, AP4, MZF1 and SP1 (Figure 7B).
The putative TF binding sites in this region were ablated
individually by site-directed mutagenesis to investigate whether
they could be responsible for its basal and vorinostat-mediated
activity (Figure 7B). The transcriptional activity of these mutated
constructs in K562 and HL60 cells indicate that the putative SP1/
MZF1 DNA binding site present in the 272/265 region is an
essential regulator of IER3 basal expression and that it is necessary
for the vorinostat-enhanced expression of this gene in these cells
(Figure 7C).
Vorinostat Transcriptional Effects are Regulated by Zinc
Finger TF
Bioinformatic analysis of the proximal promoter regions of
IER3, cFOS, COX2, p21, Cyclin G2 and CUL1 revealed GC-
rich DNA sequences to which zinc finger TFs (SP1, MZF1, ER-
alpha, MAZ, ETF) can bind (Figure S4), including motifs similar
to the GGGAGG sequence identified in IER3 (Figure 7B). Since
the transcriptional effect of HDACi on some genes depends on TF
that bind to proximal GC-rich DNA sequences, especially SP1
[19,20,21,44], we explored whether the transcriptional effect of
vorinostat one these genes could be regulated by zinc finger TF
binding to GC-rich DNA sequences. To do so, we tested whether
Mith.A, a potent inhibitor of binding of zinc finger TF, especially
SP1 to GC-rich DNA sequences, which selectively interfere with
SP1-mediated gene transcription [25,26,49,50], would affect the
transcriptional action of vorinostat. Inhibition of zinc finger TF
binding to GC-rich DNA sequences with Mith.A in K562
significantly potentiated the transcriptional effect of vorinostat on
cFOS, COX2 and Cyclin G2 but not on IER3, p21 and CUL1
(Figure 8A). In addition, Mith.A alone up-regulated IER3, cFOS,
COX2, p21, and Cyclin G2 and down-regulated CUL1 in a
fashion similar to but less marked than vorinostat. These results
suggest the involvement of GC-rich DNA sequences in basal
transcription of these genes and in the vorinostat action in the
expression of cFOS, COX2 and Cyclin G2.
To explore the involvement of SP1 in vorinostat-mediated gene
expression, we assessed the effects of SP1 knockdown via RNAi.
Transfection of K562 with siRNA against SP1 resulted only in a
maximum of 65% decrease in SP1 mRNA and protein levels, as
compared to control siRNA (Figure 8B). Nonetheless, SP1
reduction by 30–50% with SP1 specific siRNA increased by 2
fold the transcriptional effect of vorinostat on COX2 (Figure 8C),
as compared to cells transfected with control siRNA. No consistent
effects of such amounts of SP1 reduction were observed in
vorinostat-mediated expression of IER3, cFOS, p21, Cyclin G2,
and CUL1 genes between different experiments.
four independent experiments, done in duplicate. B, Average percentage of K562 cells expressing the erythroid CD235A marker and the transferin
CD71 receptor 6 SD of three independent experiments, done in triplicate. C, Average percentage of annexin-V stained apoptotic cells 6 SD obtained
in the three experiments shown in (B). D, Representative dot blots showing the expression profile of CD235A and CD71 markers and apoptosis in
K562 cells treated with vehicle and increasing concentrations of vorinostat. E, Average percentage of HL60 cells 6 SD of four independent
experiments, done in duplicate. F, Average percentage of HL60 cells on different myeloid maturation stages according the CD13/CD11b expression
profile 6 SD of four independent experiments, done in triplicate. I (CD13hi/CD11b2): myeloblasts; II (CD13lo/int/CD11b2): promyelocytes; III
(CD13lo/int/CD11b+): myelocytes and metamyelocytes; and IV (CD13hi/CD11b+): band cells and mature neutrophils. G, Average percentage of annexin-
V stained apoptotic cells 6 SD obtained in the four experiments shown in (F). H, Representative dot blots showing the expression profile of CD11b
and CD13 antigens and apoptosis in HL60 treated with vehicle, vorinostat, and DMSO. Numbers in CD13/CD11b plots are percentage of CD33 cells on
different myeloid maturation stages. Numbers in other panels are percentages of total cells in the respective gates. I, Average percentage of THP1
cells 6 SD of three independent experiments, done in duplicate or triplicate. J, Median fluorescent intensity of CD11b monocytic differentiation
marker expressed on the cell surface of THP1 cells. K, Percentage of THP1 cells expressing CD11b. L, Percentage of THP1 cells double positive for
CD11b and CD14. Values in (J, K and L) are average values 6 SD of three independent experiments, each done in triplicate. M, Average percentage of
annexin-V stained apoptotic cells 6 SD obtained in the three experiments shown in (J, K and L). N, Representative dot blots showing the expression
profile of CD11b and CD14 markers and apoptosis in THP1 cells treated with vehicle, vorinostat and PMA. *, p,0.05.
doi:10.1371/journal.pone.0053766.g002
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Vorinostat Modulates Binding of SP1 to Gene Proximal
Promoter Regions
SP1 can bind to the GC-rich DNA sequence shown to be
essential for vorinostat-mediated expression of IER3 (Figure 7B
and C) as well as to the GC-rich DNA sequences located in the
promoter regions of cFOS, COX2, p21, Cyclin G2 and CUL1
(Figure S4). ChIP assays were performed to determine whether
SP1 binds to the proximal promoter regions of these genes in
haematopoietic K562 and HL60 cells and whether vorinostat
affects its binding. In the absence of vorinostat, SP1 bound to the
proximal promoters of IER3, COX2, p21, Cyclin G2 and CUL1.
Vorinostat treatment led to significant reduction of this binding in
both cells (Figure 8D).
Discussion
There is increasing evidence that, in addition to genetic
mutations, epigenetic events play a critical role in the pathophys-
iology of haematopoietic disorders such as MDS and AML.
Accordingly epigenetic agents, i.e. hypometylating agents such as
azacytidine and decitabine, and HDACi like vorinostat and
romidepsin have been tested and shown to produce responses in
myeloid disorders both in vitro and in vivo [2,3,5,6,7,8]. Clinical
studies revealed not all AML and MDS patients respond to
vorinostat [10,13], and the precise mechanisms of action of
vorinostat on AML and MDS cells remain poorly understood. The
identification of its functional effects and potential target genes
may contribute to the identification of markers that predict
response to vorinostat, which would be extremely useful to identify
those patients most likely to respond to vorinostat. In this study, we
therefore investigated the functional and transcriptional effects of
vorinostat in MDS and AML, using human promyelocytic HL60
(AML M2/3), monocytic THP1 (AML M5), and erythroleukaemic
K562 (cells with AML M6 properties) cell lines as an in vitro model
and primary myeloid cells from AML and MDS patients to
confirm our initial findings.
Functional assays revealed vorinostat promoted cell cycle arrest,
and induced apoptosis, growth inhibition and differentiation of
HL60, K562, and THP1 cells (Figures 1 and 2 and Figures S1 and
S2). Importantly, differentiation of HL60, K562 and THP1 cell
lines was observed at concentrations of vorinostat that induced
significant growth inhibition and apoptosis, suggesting these events
are associated. However, intermediate monocytic differentiation of
THP1 was observed at vorinostat concentrations that caused cell
growth inhibition but not apoptosis. HL60 and THP1 were more
sensitive to cell cycle arrest, growth inhibition and differentiation
induced by vorinostat than K562. This observation might suggest
that the efficacy of vorinostat in promoting cellular differentiation
depends on its effect on promoting cell cycle arrest and growth
inhibition. This remains however to be established. Amongst the
three cell lines, THP1 was most sensitive to the apoptotic effect of
vorinostat and K562 least sensitive to its induction of cell cycle
arrest, growth inhibition, apoptosis and differentiation.
Importantly, vorinostat also promoted myeloid differentiation of
CD33+ cells from MDS patients and patients with AML M2, M4
and M5 types (Table 1 and Figure 3). Myeloid differentiation of
these cells was also associated with increased apoptosis, once again
suggesting these events are correlated.
The profile of gene expression produced by vorinostat in HL60,
K562, THP1 and primary myeloid cells is consistent with the
promotion of cell cycle arrest, growth inhibition, differentiation
and apoptosis of the neoplastic cells. In our experiments,
vorinostat modulated the expression of cell cycle, apoptosis, and
differentiation genes known to be altered in haematologic
malignancies, increasing expression of those genes normally
down-regulated in MDS and/or AML and suppressing genes
normally over-expressed in these malignancies (Figures 4, 5, 6).
Vorinostat up-regulated the expression of genes involved in cell
signalling (cFOS, RAI3) [7,8], cell cycle arrest (p15, p21, Cyclin
G2) [6,40,44], cell cycle checkpoint and DNA repair (RAD9A)
[45], cell differentiation (NOTCH2) [51] and down-regulated the
expression levels of important genes involved in cell cycle
transition (Cyclin D1, CUL1) [5,7,8], double strand break repair
(NBN), cell proliferation and survival (c-MYC, AXL, MZF1,
STAT5A, NFkB1, TNFRSF8) [7,30,38,39,52,53,54]. Pro-apo-
ptotic genes (e.g. IER3, p21, PPP1R13B and caspase activators)
[7,8,55] are those preferentially up-regulated (Figures 4, 5, 6).
The gene expression pattern produced by vorinostat suggest it
arrested K562 cells at the G1 and G2/M phases probably by
inducing p21 and Cyclin G2 and repressing cell cycle transition
genes CUL1, Cyclin D2, and CDK4. HL60 cells were arrested at
the G2/M phase probably through increased expression of Cyclin
D1 and p21, which are involved in cell cycle G1/S transition and
cell cycle arrest at G2/M phase, respectively. THP1 were arrested
at the G1 phase likely due to up-regulation of cell cycle arrest
genes p21 and Cyclin G2, and down-regulation of cell cycle
transition gene CDK6.
The patterns of expression of apoptosis genes generated by
vorinostat suggest HL60 cells were more sensitive to vorinostat-
induced apoptosis than K562 cells probably due to higher
expression levels of pro-apoptotic genes p21 and CD40
(Figures 4B, 5 and 4C, 6, respectively), fewer suppressed pro-
apoptotic genes (two versus four in Figure 4C, 6) and lower
induction of anti-apoptotic genes (Figure 4C, 7). Interestingly,
though vorinostat induced less pro-apoptotic genes and caused
lower modulation of these genes in THP1 than in HL60 and K562
cells, THP1 cells were substantially more sensitive to the apoptotic
effects of vorinostat. This might be attributed to substantially lower
induction of the caspase inhibitor genes IFI6 and SERPINB9 in
these cells, as compared to HL60 and K562. Another explanation
might be that THP1 apoptosis by vorinostat also relies on the
modulation of other apoptosis genes and/or non-transcriptional
effects of vorinostat such as generation of reactive oxygen species
or modulation of protein activity. This last notion is supported by
published data showing vorinostat changes cellular function via
multiple mechanisms of action [15]. This hypothesis remains to be
clarified.
Interestingly, the different pro-apoptotic gene expression
patterns in response to vorinostat amongst AML PB-CD33 and
MDS BM-CD33 cells and leukemic K562, HL60 and THP1 cells
(Figs 4, 5, 6) suggests vorinostat promoted apoptosis of these cells
via different molecular mechanisms. In primary cells, mechanisms
Figure 3. Effect of vorinostat on myeloid differentiation and apoptosis of CD33+ cells from AML and AML patients. CD33+ cells from
peripheral blood of AML patients (A) and bone marrows of MDS patients (B) were cultured in complete IMDM medium with SCF, IL-3, IL-6, GM-CSF, G-
CSF, and EPO in the presence of 1 mM vorinostat or vehicle (Control). After 3 days, myelomonocytic markers, CD11b, CD13 and CD14 and apoptosis
were analyzed by flow cytometry. The numbers in CD13/CD11b panels are percentage of CD33 cells on different myeloid maturation stages
according the CD13 and CD11b expression levels. I (CD13hi/CD11b2): myeloblasts; II (CD13lo/int/CD11b2): promyelocytes; III (CD13lo/int/CD11b+):
myelocytes and metamyelocytes; and IV (CD13hi/CD11b+): band cells and mature neutrophils. Mature monocytes are also CD13hi/CD11b+. Numbers
in other panels are percentages of total cells in the respective gates.
doi:10.1371/journal.pone.0053766.g003
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Figure 4. Effect of vorinostat on genes involved in regulation of cell cycle control, proliferation, apoptosis, and differentiation in
K562, HL60 and THP1 cells. K562 HL60, and THP1 cells were treated with vorinostat as indicated or vehicle (Control) for 4 h and gene expression
quantified by qPCR. A, Effect of vorinostat on the expression of: 1- genes with altered expression in haematologic malignancies; 2- genes with altered
expression in haematologic malignancies known to respond to epigenetic therapy; 3- transcription factors. B, Effect of vorinostat on the expression of
genes that control: 4- cell cycle arrest/check point/DNA repair and 5- cell cycle transition. C, Vorinostat effect on the expression of: 6- pro-apoptotic
and 7-anti-apoptotic genes. Results are represented as average values 6 SD from at least four independent assays, performed in triplicate, for both
cell lines. *p,0.05.
doi:10.1371/journal.pone.0053766.g004
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involving the FOXL2 and IFT57 caspase activators are likely to be
at play whereas in cell lines the mechanisms probably depend on
p21, CD40, and HIP1 proteins. Moreover, our results showing
that vorinostat–mediated down-regulation of cell cycle transition
genes was more marked in MDS than in AML cells (Figures 5 and
6), and that up-regulation of the cell cycle arresting gene p15 was
greater in AML than in MDS cells suggest that vorinostat
promotes cell cycle arrest of these primary myeloid cells through
different molecular mechanisms. In MDS BM-CD33 cells these
mechanisms involve the Cyclin D2, CDK4 and CDK6 proteins,
whereas in AML cells the mechanisms are dependent on p15. This
hypothesis is supported by published data showing p15 is one of
the genes most frequently inactivated in leukaemic patients by
DNA methylation and that p15 methylation in AML patients is
associated with poor prognosis [40,41].
Our findings showing vorinostat induced terminal differentia-
tion of HL60 but only partial erythroid differentiation of K562
(Figure 2 and Figure S2) suggest vorinostat causes differentiation in
a cell line specific manner. Since K562 cells can undergo terminal
erythroid differentiation by other HDACi (e.g. apicidin) [56], the
different effects of vorinostat in HL60 and K562 differentiation
might partially result from the different gene expression profiles
(e.g. p15, c-MYC, apoptosis genes) in response to vorinostat
amongst K562 and HL60 cells (Figure 4). Our results showing
vorinostat promoted monocytic terminal differentiation of only a
very small proportion of THP1 cells (less than 6% in Figure 2L
and N) may be explained by the high rate of apoptosis at the
vorinostat concentrations required for terminal differentiation.
Overall, the effects of vorinostat in growth inhibition and
differentiation of malignant haematopoietic cells shown herein
may be, at least partially, mediated through the modulation of the
expression of genes that control proliferation, apoptosis and
differentiation such as cFOS, COX2, IER3, p21, p15, RAI3,
Cyclin D1, c-MYC, AXL and MZF1 [7,8,30,38,39,42]. The
importance of p21 up-regulation in the vorinostat functional
effects is supported by its important role in controlling cell
proliferation, apoptosis and differentiation and data showing the
p21 gene is activated by most of the tested HDAC inhibitors,
suggesting that p21 might in part mediate the antiproliferation and
differentiation effects of these drugs [44,57]. The importance of c-
MYC down-regulation is supported by its important role in
haematopoiesis/leukaemogenesis and data showing that its down-
Figure 5. Effect of vorinostat on genes involved in regulation of cell cycle control, proliferation, apoptosis, and differentiation in
CD33 myeloid cells from AML patients. PB-CD33 cells from AML patients were treated with 5 mM vorinostat or vehicle (Control) for 8 h and gene
expression quantified by qPCR. A, Effect of vorinostat on the expression of genes responsive to vorinostat in K562, HL60 and THP1 cells; 1- genes with
altered expression in haematologic malignancies; 2- genes with altered expression in haematologic malignancies that respond to epigenetic therapy;
and 3- transcription factors. B, Effect of vorinostat on the expression of genes that control: 4- cell cycle arrest/check point/DNA repair and 5- cell cycle
transition. C, Effect of vorinostat on the expression of: 6- pro-apoptotic and 7-anti-apoptotic genes. In all panels, each dot represents data from one
patient. *p,0.05.
doi:10.1371/journal.pone.0053766.g005
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regulation is critical for valproic acid induced growth arrest and
myeloid differentiation of AML cells [39,58].
Analysis of the promoter regions of IER3, cFOS and COX2,
some of the most responsive genes, identified vorinostat responsive
elements within proximal promoter regions (Figure 7A and Figure
S3). Subsequent ablating mutation of a putative SP1/MZF1
binding site within the proximal IER promoter markedly reduced
basal and abrogated vorinostat-induced promoter activity
(Figure 7B and C). Analysis of proximal IER3, cFOS, COX2,
p21, Cyclin G2 and CUL1 promoter sequences showed they
contain GC-rich DNA sequences to which SP1 and other zinc
finger TF can bind, including similar motifs to the SP1/MZF1
present in the IER3 promoter (Figure S4). Furthermore, inhibition
of transcriptional activity mediated by GC-rich DNA sequences
with Mith.A, a compound that binds to GC-rich DNA sequences
and interferes with zinc finger TF binding, especially SP1 [49,50],
potentiated the effects of vorinostat on the expression of cFOS,
COX2 and Cyclin G2, and changed basal expression of IER3,
cFOS, COX2, p21, Cyclin G2 and CUL1 in the same fashion as
vorinostat though to a much less extent (Figure 8A). In addition,
30–50% reduction of SP1 with specific siRNA increased
vorinostat-induced COX2 expression by 2 fold (Figure 8B–C).
Finally, ChIP assays showed SP1 binds to the proximal promoter
regions of all these genes except cFOS and that vorinostat
decreased its binding to IER3, p21, Cyclin G2 and CUL1
(Figure 8D). SP1 binding to proximal COX2 region was lower as
compared with other genes but consistently decreased by
vorinostat.
Although these findings do not show direct evidence for the
involvement of SP1 via GC-rich DNA elements in the transcrip-
tional modulation of these genes by vorinostat, they clearly
demonstrate that vorinostat-mediated IER3 transcription relies on
Figure 6. Effect of vorinostat on genes involved in regulation of cell cycle control, proliferation, apoptosis, and differentiation in
CD33 myeloid cells from MDS patients. BM-CD33 cells from MDS patients were treated with 5 mM vorinostat or vehicle (Control) for 8 h and
gene expression quantified by qPCR. A, Effect of vorinostat on the expression of genes responsive to vorinostat in K562, HL60 and THP1; 1- genes
with altered expression in haematologic malignancies; 2- genes with altered expression in haematologic malignancies that respond to epigenetic
therapy; and 3- transcription factors. B, Effect of vorinostat on the expression of genes that control: 4- cell cycle arrest/check point/DNA repair and 5-
cell cycle transition. C, Effect of vorinostat on the expression of: 6- pro-apoptotic and 7-anti-apoptotic genes. In all panels, each dot represents data
from one patient. *p,0.05.
doi:10.1371/journal.pone.0053766.g006
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Figure 7. Identification of vorinostat responsive elements in the IER3 promoter. A, K562 cells were transfected with pGL3-basic vector or a
series of IER3 reporters as indicated plus b-galactosidase vector, and then treated with vorinostat (2 mM) or vehicle (Control) for 24 h and reporter
activity measured. Results are shown as average fold luciferase/b-galactosidase induction versus control cells transfected with pGL3 6 S.D. from one
representative of at least three independent assays done in triplicate using each reporter construct at least from two different clones. B, Scheme of
wild type and mutated 2124/+32 reporter constructs showing the 291 to 243 nucleotide sequence of IER3 promoter containing the putative TF
binding sites present in the 291/261 region (lane 1) and the mutated nucleotides for the different TF binding sites present in this region (lanes 2 to
6). The mutated nucleotides present in the mutant luciferase reporter plasmids for the different TF binding sites are boldfaced and underlined. +1,
denotes transcription start site. C, K562 and HL60 cells were transfected with pGL3-basic vector or with wild type and mutated 2124/+32 IER3
reporter constructs for the indicated TF plus b-galactosidase vector and the rest of the procedure was done as in (A).The results are average fold
luciferase/b-galactosidase induction versus control cells transfected with pGL3 6 S.D. from one representative assay done in triplicate using mutated
plasmids for the same putative TF binding site from different clones, of at least three independent assays performed in both K562 and HL60 cells.
Data were analyzed using the ANOVA and the Tukey-Kramer multiple comparison test. *p,0.05.
doi:10.1371/journal.pone.0053766.g007
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Figure 8. Effect of GC-rich DNA sequences and SP1 on the transcriptional effect of vorinostat on IER3, cFOX, COX2, p21, Cyclin G2
and CUL1 genes. A, K562 cells were exposed to Mith.A (100 nM) or vehicle (Control) and not further treated or exposed 30 min later to 5 mM
vorinostat for 8 h and gene expression quantified by qPCR. Results are average values 6 SEM of at least three independent assays, done in triplicate.
B–C, K562 cells were transfected with control (Ctr) or SP1 siRNA and treated with vehicle or vorinostat (2 mM) for 24 and 48 h. B upper panel,
immunoblot showing SP1 protein levels in cells transfected with control (Ctr) and SP1 siRNAs in 1 out of 5 assays at 48 h after transfection. B lower
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GC-rich DNA sequences located in its proximal promoter, and
point to a role of these regulatory regions and zinc finger TF, e.g.
SP1, in the transcriptional effects of vorinostat in these genes
[49,50]. Namely, that GC-rich DNA sequences are involved in
vorinostat-mediated expression of IER3, cFOS, COX2 and Cyclin
G2. Also they suggest that the transcriptional effect of vorinostat in
IER3, COX2, p21, Cyclin G2, and CUL1 might have occurred
through a mechanism dependent on the dissociation of SP1 from
their proximal promoters, which cannot be attributed to its down-
regulation by vorinostat (Figure 4A, 3). Whether the transcrip-
tional modulation by vorinostat relies on SP1 dissociation from
GC-rich DNA sequences remains however to be established. The
observations that i) ablation of the SP1/MZF1 site within the
proximal IER3 promoter decreased basal and impaired vorinostat-
induced transcription and ii) vorinostat decreased SP1 binding to
proximal IER3 region, suggest that vorinostat either disrupted SP1
binding from a downstream SP1 consensus motif (Figure S4) or
that vorinostat disrupted SP1 binding from this site allowing the
recruitment of others zinc finger TFs that acted as transcriptional
activators of IER3 in the absence of SP1. Furthermore, the fact
that Mith.A potentiated vorinostat-induction of cFOS expression
and no SP1 binding to its proximal promoter was found indicates
that vorinostat-mediated transcription of this gene is probably
dependent on other zinc finger TFs.
Our results are in conformity with increasing data showing that
gene-modulation by HDACi (vorinostat, butyrate, TSA, apicidin,
valproic acid) is mediated via SP1 motifs through SP family TFs
[18,20,59]. Transcriptional activation or repression by SP1
depends on the promoter context it binds to and on the co-
activators and co-repressors it interacts with. These interactions
and direct binding competition between SP1 and other zinc finger
TFs are important in the transcriptional regulation of genes with
GC-rich DNA sequences located proximal to transcription
initiation site. SP1 has been shown to repress transcription of
several genes including p21 by recruiting HDAC and co-repressors
complexes such as NCo-R, SMRT, and NuRD, to their proximal
promoters [18,21,60]. Accordingly, HDACi-mediated expression
of these genes acted via disruption of SP1 binding from their
promoters [18,20,59]. For some genes, e.g. Cyclin G2, SP1-
dependent recruitment of HDAC and co-repressors involved SP1
interaction with other zinc finger TF such as ER-alpha at the GC-
rich motifs in its proximal promoter region [61,62]. Our results are
also consistent with recent data showing that acetylation of SP1 by
HDACi decreases its DNA binding affinity allowing binding of
weaker affinity zinc finger TFs, e.g. SP3, to the same site which
can act as transcriptional activators or repressors [19,20].
Whether modulation of MZF1 expression (Figure 4A, 3) and/or
activity by vorinostat accounts for the transcriptional effects of
vorinostat on these genes is a question that remains to be
elucidated. However, since MZF1 can repress transcription via
recruitment of HDAC to gene promoters [63] and some of these
genes have putative binding sites for MZF1 (Figure S4), it is
plausible that MZF1 may play a role in vorinostat-mediated
transcriptional regulation of some of these genes.
In conclusion, these results identify new vorinostat-responsive
genes in leukemic cells and, most important, in primary myeloid
cells from AML and MDS patients, some of them often
deregulated in these malignancies, and implicated in their
pathogenesis, and point to a strong correlation between the
functional and transcriptional effects of vorinostat. Moreover, they
show IER3 transcription by vorinostat is mediated by proximal
promoter GC-rich DNA sequences, and suggest regulation by GC-
rich DNA sequences and SP1 are involved in vorinostat action in
some of these genes. Confirmation of this data in the course of
clinical trials might shed further light of the usefulness of this drug
in the treatment of myeloid disorders.
Supporting Information
Figure S1 Effect of vorinostat on cell cycle progression
and apoptosis of K562 and HL60 cells. A-B, K562 cells were
cultured with 5 mM vorinostat or vehicle (Control) and cell cycle
distribution analyzed 24 h thereafter by flow cytometry. A,
Average percentage of K562 cells in each phase of the cell cycle
6 SD of three independent assays, done in triplicate. B,
Representative histograms obtained in K562 showing the effect
of vorinostat in K562 cell cycle progression. Cells arrested in the
G1 phase, 2 N DNA content; cells arrested in S phase; and cells
arrested in the G2/M phase (4 N DNA content). C–D, K562 and
HL60 cells were treated with vorinostat or vehicle (Control) as
indicated. After 72 h, apoptosis was determined by flow
cytometry. C, Average percentage of apoptotic K562 and HL60
cells 6 SD of three independent experiments, done in duplicate.
D, Representative dot blots showing the percentage of apoptotic
K562 and HL60 cells cultured for 72 h in the absence and in the
presence of vorinostat. Numbers are percentage of total cells in the
respective gates. *p,0.05.
(TIF)
Figure S2 Effect of vorinostat on terminal erythroid
differentiation of K562 cells. K562 cells were treated with
vorinostat or vehicle (Control) as indicated. After 4 days, terminal
differentiation of K562 was examined by measuring Hb content
by ELISA and by microscopy of benzidine (to detect Hb) plus
Giemsa stained cells. A, Quantification of hemoglobin content in
K562 cells cultured in the presence of vorinostat and vehicle from
two different assays, each done in triplicate. Results are expressed
as nanograms of Hb per micrograms of total cellular protein 6 SD
(n = 3) in two independent assays. B, benzidine-Giemsa stain of
K562 cultured in the absence and in the presence of 2 mM
vorinostat during 4 days from two independent assays. Similar
results were obtained in K562 cells after 3 and 5 days in culture in
the absence and presence of vorinostat.
(TIF)
Figure S3 Identification of vorinostat responsive ele-
ments in the cFOS and COX2 promoters. A, K562 and
HL60 cells were transiently co-transfected with pGL3-bascic
vector or reporter constructs containing different DNA sequences
of the cFOS promoter cloned into the pGL3-luciferase reporter
along with b-galactosidase control vector as indicated. 1 h after
transfection the cells were treated with 2 mM vorinostat or vehicle
(Control). Cell lysates were obtained 24 h after and assayed for
luciferase and b-galactosidase activities. Luciferase activities were
panel, SP1 mRNA levels in cells transfected with control (Ctr) and SP1 siRNAs. Graph shows average percentage of SP1 mRNA 6 S.D. from 5
independent assays at 24 h after transfection. C, Graph shows average mRNA fold change of the indicated genes over vehicle treated cells
transfected with the same siRNA 48 h after transfection 6 SEM from 3 independent experiments. D, K562 and HL60 cells were treated with vorinostat
(5 mM) or vehicle (Control) for 7 h and SP1 binding to the proximal promoter regions of the indicated genes determined by ChIP assays and qPCR.
Results are expressed as fold change over control IgG and represent average values of at least three independent experiments 6 SEM. Data were
analyzed using paired Student’s t test. *p,0.05. **p,0.05.
doi:10.1371/journal.pone.0053766.g008
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normalized to b-galactosidase units in the same samples. B, K562
and HL60 cells were transiently co-transfected with pGL3-bascic
vector or reporter constructs containing different DNA sequences
of the COX2 promoter cloned into the pGL3-luciferase reporter
along with b-galactosidase control vector as indicated and the rest
of the procedure was done as in (A). Results in (A and B) are
average fold induction 6 S.D versus control cells transfected with
pGL3-basic of one of three independent assays, done in triplicate,
using each reporter plasmid at least from two different clones.
Data were analyzed using the ANOVA and the Tukey-Kramer
multiple comparison test. *p,0.05.
(TIF)
Figure S4 Scheme of the proximal promoter regions of
IER3, COX2, cFOS, p21, Cyclin G2 and CUL1 genes.
Promoter regions of indicated genes were analyzed for the
presence of TF binding sites by using the online Transcription
Element Search System. The putative binding sites for SP1 and
other zinc finger transcription factors present in these sequences
are shown. Motifs identical or similar to the GGGAGG motif
present in IER3 271/266 promoter region, which is crucial to its
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